Montelukast: 4 agencies, 2004–2020
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused montelukast: all 6 decisive outcomes across 3 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 16.1 years separate the first record, 9 Aug 2004 at SMC (Scotland), from the most recent, 24 Sep 2020 at PHARMAC (New Zealand).
SMC (Scotland) changed its position: recommended on 9 Aug 2004, restricted by 9 Jul 2007.
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2020; on this evidence the file is dormant.
4 distinct indication wordings are recorded for montelukast by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess montelukast, on 9 Aug 2004; PHARMAC (New Zealand) did not open a file until 5 Aug 2010 — a wide spread of 6 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 9 years in total.
Restriction is doing real work here: 2 of 6 decisive outcomes narrowed montelukast to a subgroup rather than accepting or refusing it outright, at SMC (Scotland).
3 of the 4 agencies here assessed montelukast more than once, PHARMAC (New Zealand) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed montelukast.
The full ledger for montelukast reads 4 recommended, 4 other, 2 advice and 2 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 24 Sep 2020 | Asthma - exercise induced (EIA) | PTAC advice: Medium · decision reached | source |
| PHARMAC (New Zealand) | 24 Sep 2020 | Asthma - preschool wheeze | PTAC advice: No Formal Recommendation · decision reached | source |
| HAS (France) | 4 Nov 2009 | Listing (Transparency Committee) | ASMR V | source |
| SMC (Scotland) | 9 Jul 2007 | Asthma in Children aged 2 -14 years | accepted (restricted) | source |
| AWMSG (Wales) | 15 Mar 2005 | Treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately con… | outside AWMSG criteria | source |
8 further decisions for montelukast, across 3 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- mepolizumab — same ATC class R03D — Obstructive airway diseases
- omalizumab — same ATC class R03D — Obstructive airway diseases
- benralizumab — same ATC class R03D — Obstructive airway diseases
- tezepelumab — same ATC class R03D — Obstructive airway diseases
- depemokimab — same ATC class R03D — Obstructive airway diseases
- roflumilast — same ATC class R03D — Obstructive airway diseases
Coverage: 13 decisions for montelukast from 4 agencies, 2004 to 2020. Data to 7 Sep 2026. ATC class R03D — Obstructive airway diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.